European Commission clears AstraZeneca's $39B bid for Alexion and a future in rare diseases. Now there's just a final hurdle
AstraZeneca has cleared the penultimate hurdle before officially completing its $39 billion acquisition of Alexion.
The European Commission has given its blessing to the proposed deal after a review, the latest green light following clearances by the United States’ FTC and its counterparts in 11 countries. The UK’s CMA will be the last one to decide — and it has until July 21.
Assuming an OK, AstraZeneca has previously said it expects to close the deal in Q3.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 113,500+ biopharma pros reading Endpoints daily — and it's free.